topiramate and Chorea

topiramate has been researched along with Chorea* in 5 studies

Trials

1 trial(s) available for topiramate and Chorea

Article	Year
Topiramate therapy for paroxysmal kinesigenic choreoathetosis. Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:1 We observed the clinical efficacy of topiramate for paroxysmal kinesigenic choreoathetosis (PKC). Topiramate was administered as a monotherapy with titrated dosages to 8 patients with PKC. Target daily dose of topiramate was 100 to 200 mg; the follow-up period ranged from 8 months to 2 years. All of the patients became attack-free, and side effects were mild. The results show that topiramate is effective as a monotherapy for treating patients with PKC. The response to topiramate indicates that the disease may be caused by an ion channel defect. Topics: Adolescent; Adult; Anticonvulsants; Athetosis; Child; Chorea; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Fructose; Humans; Male; Topiramate; Treatment Outcome	2005

Article

Year

Topiramate therapy for paroxysmal kinesigenic choreoathetosis.

Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:1

We observed the clinical efficacy of topiramate for paroxysmal kinesigenic choreoathetosis (PKC). Topiramate was administered as a monotherapy with titrated dosages to 8 patients with PKC. Target daily dose of topiramate was 100 to 200 mg; the follow-up period ranged from 8 months to 2 years. All of the patients became attack-free, and side effects were mild. The results show that topiramate is effective as a monotherapy for treating patients with PKC. The response to topiramate indicates that the disease may be caused by an ion channel defect.

Topics: Adolescent; Adult; Anticonvulsants; Athetosis; Child; Chorea; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Fructose; Humans; Male; Topiramate; Treatment Outcome

2005

Other Studies

4 other study(ies) available for topiramate and Chorea

Article	Year
Hemichorea-hemiballismus in the setting of posterolateral putaminal lesion and treatment with topiramate. Journal of the neurological sciences, 2017, 04-15, Volume: 375 Topics: Anticonvulsants; Brain; Brain Ischemia; Chorea; Dyskinesias; Female; Fructose; Humans; Middle Aged; Stroke; Topiramate	2017
Topiramate improves glucose metabolism in choreatic and depressive patient: PET findings. The Journal of neuropsychiatry and clinical neurosciences, 2007,Summer, Volume: 19, Issue:3 Topics: Chorea; Depression; Fructose; Glucose; Humans; Male; Middle Aged; Neuroprotective Agents; Positron-Emission Tomography; Topiramate	2007
Efficacy and tolerability of topiramate in vascular generalized chorea. The Annals of pharmacotherapy, 2007, Volume: 41, Issue:11 Topics: Aged; Anticonvulsants; Chorea; Female; Fructose; Humans; Topiramate; Vascular Diseases	2007
Vascular hemichorea/hemiballism and topiramate. Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:7 Although vascular hemichorea/hemiballism (HC/HB) has been reported to be self-limited, in some cases, it can be irreversible and severely disabling. The standard treatment includes typical and atypical neuroleptics and GABA-mimetic drugs. Topiramate is a new antiepileptic drug possessing a complex mechanism of action, including the enhancement of GABA-mediated inhibition. We describe a 71-year-old patient with HC/HB who markedly improved after topiramate treatment. Topics: Aged; Anticonvulsants; Basal Ganglia; Chorea; Dyskinesias; Fructose; Humans; Magnetic Resonance Imaging; Male; Stroke; Topiramate	2004